AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01948011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racecadotril suspension
Description: Racecadotril suspension at 10, 30 and 60mg. Single oral dose.
Study NCT02791334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV
Study NCT01948011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril granules
Description: Racecadotril granules at 60mg. Single oral dose.
Study NCT02878239 — intervention group
Intervention type: OTHER
Intervention: Steps 1
Description: Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.
Study NCT02878239 — intervention group
Intervention type: OTHER
Intervention: Steps 2
Description: Kinematic characteristics are obtained by the portal gait analysis system in the subjects.Physical examinations are taken to avoid other diseases.
Study NCT02791334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02791334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT02791334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally
Study NCT02791334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3321367
Description: Administered IV
Study NCT04213794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Undergo HIPEC with doxorubicin and cisplatin
Study NCT04213794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery
Description: Undergo cytoreduction
Study NCT04213794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Undergo HIPEC with doxorubicin and cisplatin
Study NCT04213794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: Undergo HIPEC with doxorubicin and cisplatin
Study NCT04213794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Given IV
Study NCT04213794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04213794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04213794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04213794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03716830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: verum acupuncture
Description: Participants will receive real acupuncture treatment.
Study NCT03698773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Access to routine information
Description: Access to routine pain-control information
Study NCT03716830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham acupuncture
Description: Participants will receive sham acupuncture treatment.
Study NCT03716830 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Participants will receive sham acupuncture treatment.
Study NCT03716830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS
Description: Participants will receive real transcranial direct current stimulation.
Study NCT03716830 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Participants will receive sham transcranial direct current stimulation.
Study NCT03716830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: Participants will receive sham transcranial direct current stimulation.
Study NCT00983255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA for injection, 200 mg/vial
Description: TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 \& 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
Study NCT00983255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA tablets
Description: TR-701 FA will be given once orally as a 200 mg tablet in Part C.
Study NCT04854707 — intervention group
Intervention type: DRUG
Intervention: Follitropin Alfa
Description: Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH or agonist of GnRH.
Study NCT04854707 — intervention group
Intervention type: DRUG
Intervention: Follicle Stimulating Hormone/Luteinizing Hormone
Description: Subcutaneous injection of follitropin alpha biosimilar, with daily dose 100-300 IU for at least 5 days, than added another gonadotropin for a maximum of 10 days, using antagonists of GnRH or agonist of GnRH.
Study NCT04854707 — intervention group
Intervention type: DRUG
Intervention: Follitropin Alfa
Description: Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH only for suppression.
Study NCT04854707 — intervention group
Intervention type: DRUG
Intervention: Follitropin Alfa
Description: Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using agonists of GnRH only for suppression.
Study NCT04854707 — intervention group
Intervention type: DRUG
Intervention: Follicle Stimulating Hormone/Luteinizing Hormone
Description: Overall ovarian stimulation protocols with follitropin alpha biosimilar for at least 5 days+other recombinant and menotropins and short (antagonists of GnRH) or long protocol (agonist of GnRH).
Study NCT03698773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to website
Description: Access to informational website: thepainlesspush.com
Study NCT00532779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone SR 16 mg/Bupropion SR 360 mg /day
Study NCT00532779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone SR 32 mg/Bupropion SR 360 mg /day
Study NCT00532779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00532779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ancillary therapy
Description: Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
Study NCT00532779 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ancillary therapy
Description: Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
Study NCT01937546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary delivery of anterior shoulder
Study NCT01937546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary delivery posterior shoulder
Study NCT00958698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Ancillary studies
Study NCT00958698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Ancillary studies
Study NCT00958698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Ancillary studies
Study NCT00958698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosocial Assessment and Care
Description: Ancillary studies
Study NCT00958698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00958698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00958698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00958698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02332655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.~The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed.
Study NCT00864084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
Study NCT04482101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Root canal obturation
Description: Root canal filling
Study NCT03855930 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: During the study, standard motor and sensory paradigms will be performed to establish anatomical and functional patterns in the non-painful state. The patient will then be asked to urinate (to an external collecting tube system).
Study NCT04874701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsimax
Description: Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg
Study NCT04874701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy restriction
Description: Personalised diet plan targeting a 500 kcal/day energy restriction
Study NCT04874701 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Energy restriction
Description: Personalised diet plan targeting a 500 kcal/day energy restriction
Study NCT01843660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl-Paracetamol
Description: Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram \[mg\] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
Study NCT01048411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naja-comp.
Description: homeopathic remedy
Study NCT01048411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: s.c. injection of NaCl-solution three times a week
Study NCT03770182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUROLITH
Description: transcranial pulse stimulation (TPS)
Study NCT00880867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: An accessible site of disease (lymph node, cutaneous, subcutaneous, etc.) will be selected by the principal investigator. Patients will then receive two doses of low dose irradiation (2 Gy per day) to that single site on days 1 and 2. Intratumorally or peritumorally Poly-ICLC will be dosed on days 3 and 4 by the physician during weeks 1, 2, 3, 4, and 8.
Study NCT02842268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Test product dried for at least 15 minutes.Subjects to ride for 30 minutes on a stationary bicycle.(Formulation Number :Y73-161)
Study NCT02155595 — intervention group
Intervention type: OTHER
Intervention: 500 without BP treatment
Description: lab tests, X-ray, bone scan or MRI, as needed
Study NCT02155595 — intervention group
Intervention type: OTHER
Intervention: 500 with BP treatment
Description: lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
Study NCT04002674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days).
Study NCT04002674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib Oral Capsule
Description: Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
Study NCT00434096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimonabant (SR141716)
Description: oral administration once daily
Study NCT00434096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration once daily
Study NCT04141462 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood test
Study NCT03266562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: F-18 FES
Description: Evaluate uptake of F-18 FES in breast tissue
Study NCT03266562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: F-18 FDG
Description: Evaluate uptake of F-18 FDG in breast tissue
Study NCT04328493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate
Description: Each chloroquine tablet contains 250mg chloroquine phosphate (or 150mg chloroquine base). Chloroquine treatment for patient is weight-based dosing.~Chloroquine will be administered orally, as tablets. For unconscious patients chloroquine can be crushed and administered as a suspension via a nasogastric tube.~The total duration of treatment with Chloroquine will be 10 days
Study NCT00705575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)
Description: During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.
Study NCT00705575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren (300 mg)
Description: During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.
Study NCT02504060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch Placebo
Study NCT02504060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-D-glucosamine
Study NCT03659032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pediatric Manual Therapy
Study NCT03659032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Educational Physical Therapy
Study NCT02786810 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sulfur hexafluoride type-a lipid microspheres
Description: Used as a contrast to enhance renal ultrasound
Study NCT01556646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: 15 to 30mg qd titrated to sodium concentration
Study NCT02362243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Intervention
Description: Participants will perform the back and core exercises that were tested in our previous firefighter study (Mayer, 2015), in addition to their usual physical fitness routine. All participants at a given fire station will receive the same intervention and all interventions will be completed at the fire station. Participants will perform 2 exercise sessions each week (each time they are on duty) throughout the study's 12-month duration. The back and core exercise program consists of 1 set of 5 exercises - 4 core exercises on a floor mat and 1 back extension exercise on a variable angle Roman chair - which will take approximately 10 minutes to complete for each session (Mayer, 2015).
Study NCT04112433 — intervention group
Intervention type: DEVICE
Intervention: PURE EP 2
Description: Enrolled patients receiving cardiac ablation treatment using the current standard of care with additional monitoring and intracardiac electrogram signal collection via the PURE EP 2 system.
Study NCT03835260 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pivot Breath Sensor
Description: The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
Study NCT04083872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D744 Cap. 1 Cap., single oral administration under fasting condition
Study NCT04083872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
Study NCT04006158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED bed
Description: Low risk FDA cleared full body LED bed
Study NCT02968199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A brief intervention
Description: The content of the intervention includes: (1) asking about tobacco use; (2) advising cessation; (3) assessing willingness to quit; (4) assisting in the attempt to quit; and (5) arranging follow-up.
Study NCT04103294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cowpea variety #1
Description: two most popular varieties of cowpea currently consumed in the selected geographic area
Study NCT04103294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cowpea variety #2
Description: two most popular varieties of cowpea currently consumed in the selected geographic area
Study NCT00782652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled nitric oxide
Description: Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
Study NCT00782652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nitrogen gas
Description: Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
Study NCT02479919 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim® Active TBS
Description: Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
Study NCT02479919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim® Active TBS
Description: Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
Study NCT02479919 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim® Sham TBS
Description: Sham stimulation
Study NCT02647034 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT01901380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Extensively hydrolyzed casein formula + LGG
Study NCT03068299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: Sessions of sixty minutes each, which will take place weekly, totaling 24 weeks (6 months). Ten minutes from the start of each session will be reserved for initial exercises, with movements of the upper limbs, lower, accompanied by a motivational music. The process of identifying and memorizing the movements will be carried out as many times as the group deems necessary. The rhythms include combinations of circular and ballroom dances, including waltz, cha-cha-cha, cancan, among others. In all the sessions, the last fifteen minutes are reserved for a conversation about the dance learned/practiced in the day. It is expected to have reached the proposal of a practice of 15 different choreographies and that this was a pleasant moment for all the participants.
Study NCT03068299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health care guidance
Description: Control group will receive attention, through guidelines for care and health practices for the caregiver and the elderly care recipient. This attention should occur in the same number of sessions of the dance and group intervention group. The control group should follow the same subdivision of the intervention group, in terms of the number of participants per subgroup. The subjects of the guidelines will be raised by the demand of the participants themselves and then worked in an interdisciplinary way.
Study NCT00643955 — intervention group
Intervention type: OTHER
Intervention: muscle strength
Description: muscle strength
Study NCT03754699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: During the usual pre-anesthesia assessment (performed between D-30 and D0 of the intervention), the anesthesiologist will deliver to the intervention group patient oral and visual information on:~* the numerical scale of pain ranging from 0 to 10 with examples of perceptions corresponding to each level of the scale (calibration)~* nature of postoperative pain (inflammatory character, dynamic over time)~* average pain level incurred by the intervention~* the difference between anti-inflammatory and opioid analgesics~* principles of systematic treatment and pain anticipation~* principles of overdose and side effects prevention This information is standardized and delivered orally, accompanied by a visual support (patient diary), which will be given to the patient upon discharge from the hospital
Study NCT03754699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard information
Description: Standard information on pain For patients in the control group the standardized information is based on the SG/DGM/DSS 1/41-2010 scheme of the AFSSAPS-CFETD repository.
Study NCT03428516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed CPAP
Description: CPAP is a device that applies continous fixed positive pressure to the airways in order to keep them opened during sleep